PMID- 3144655
OWN - NLM
STAT- MEDLINE
DCOM- 19890209
LR  - 20190726
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 27
IP  - 11
DP  - 1988 Nov
TI  - Effects of dopaminergic and serotonergic receptor blockade on neurochemical 
      changes induced by acute administration of methamphetamine and 
      3,4-methylenedioxymethamphetamine.
PG  - 1089-96
AB  - As dopamine (DA) causes neurochemical changes in the central serotonergic system 
      after an acute injection of methamphetamine, the present study examined the 
      possibility that this response is mediated through dopaminergic receptors. 
      Pretreatment with the DA receptor antagonist, haloperidol, failed to prevent the 
      decreases in the activity of tryptophan hydroxylase and the concentration of 
      serotonin (5-HT) in the frontal cortex, hippocampus and neostriatum 1 hr after a 
      single administration of methamphetamine. Because methamphetamine is also a 
      potent releaser of 5-HT, the possibility that 5-HT receptors mediate the effects 
      of methamphetamine was evaluated. Pretreatment with methiothepin an antagonist of 
      both DA and 5-HT receptors, failed to prevent the decline in activity of 
      tryptophan hydroxylase but did attenuate the decreases in concentrations of 5-HT 
      measured in the frontal cortex and hippocampus. This attenuation is not mediated 
      through 5-HT2 receptors, as ritanserin failed to interfere with the changes 
      induced by methamphetamine. In addition, DA or 5-HT receptors were apparently not 
      involved in the changes in activity of tryptophan hydroxylase and concentrations 
      of 5-HT induced by another analogue of amphetamine, 
      3,4-methylenedioxymethamphetamine (MDMA). This study suggests different 
      mechanisms are responsible for the acute and long-term changes observed in the 
      central serotonergic system following a single or multiple doses of 
      methamphetamine.
FAU - Johnson, M
AU  - Johnson M
AD  - Department of Pharmacology and Toxicology, University of Utah, Salt Lake City 
      84112.
FAU - Hanson, G R
AU  - Hanson GR
FAU - Gibb, J W
AU  - Gibb JW
LA  - eng
GR  - DA 00869/DA/NIDA NIH HHS/United States
GR  - DA 04222/DA/NIDA NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Amphetamines)
RN  - 0 (Piperidines)
RN  - 0 (Receptors, Dopamine)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Serotonin Antagonists)
RN  - 145TFV465S (Ritanserin)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 55D94103HL (Methiothepin)
RN  - J6292F8L3D (Haloperidol)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/administration & dosage/*pharmacology
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Haloperidol/pharmacology
MH  - Male
MH  - Methamphetamine/administration & dosage/*pharmacology
MH  - Methiothepin/pharmacology
MH  - Piperidines/pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Receptors, Dopamine/*drug effects/physiology
MH  - Receptors, Serotonin/*drug effects/physiology
MH  - Ritanserin
MH  - Serotonin Antagonists/pharmacology
EDAT- 1988/11/01 00:00
MHDA- 1988/11/01 00:01
CRDT- 1988/11/01 00:00
PHST- 1988/11/01 00:00 [pubmed]
PHST- 1988/11/01 00:01 [medline]
PHST- 1988/11/01 00:00 [entrez]
AID - 10.1016/0028-3908(88)90002-0 [doi]
PST - ppublish
SO  - Neuropharmacology. 1988 Nov;27(11):1089-96. doi: 10.1016/0028-3908(88)90002-0.